Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
$0.41
+10.5%		$0.61
$0.36
▼
$9.76
$57.58M1.75969,211 shs734,001 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$0.86
+0.5%		$1.27
$0.76
▼
$3.31
$58.60M1.441.71 million shs580,341 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$0.38
+0.6%		$0.40
$0.29
▼
$3.53
$56.30M2.23254,181 shs172,916 shs
Palatin Technologies stock logo
PTN
Palatin Technologies
$7.70
-1.4%		$11.20
$5.00
▼
$31.00
$13.71M0.6320,137 shs5,846 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
0.00%-4.94%-31.50%-45.63%-93.39%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
0.00%+3.45%-32.65%-49.98%-65.65%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.00%-0.65%-9.35%-12.43%-78.42%
Palatin Technologies stock logo
PTN
Palatin Technologies
0.00%-0.13%-33.56%-61.94%+769,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
$0.41
+10.5%		$0.61
$0.36
▼
$9.76
$57.58M1.75969,211 shs734,001 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$0.86
+0.5%		$1.27
$0.76
▼
$3.31
$58.60M1.441.71 million shs580,341 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$0.38
+0.6%		$0.40
$0.29
▼
$3.53
$56.30M2.23254,181 shs172,916 shs
Palatin Technologies stock logo
PTN
Palatin Technologies
$7.70
-1.4%		$11.20
$5.00
▼
$31.00
$13.71M0.6320,137 shs5,846 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
0.00%-4.94%-31.50%-45.63%-93.39%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
0.00%+3.45%-32.65%-49.98%-65.65%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.00%-0.65%-9.35%-12.43%-78.42%
Palatin Technologies stock logo
PTN
Palatin Technologies
0.00%-0.13%-33.56%-61.94%+769,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
1.00
SellN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.17
Hold$7.50776.78% Upside
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.00
Hold$5.501,339.79% Upside
Palatin Technologies stock logo
PTN
Palatin Technologies
3.00
Buy$55.00614.29% Upside

Current Analyst Ratings Breakdown

Latest PTN, IMMP, CRDF, and AIFC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/14/2026
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/10/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/17/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy
6/3/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$2.00
6/1/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
6/1/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/18/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
$24.84M2.32N/AN/A$9.07 per share0.05
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$590K99.31N/AN/A$0.67 per share1.28
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$6.69M8.41N/AN/A$0.63 per share0.61
Palatin Technologies stock logo
PTN
Palatin Technologies
$4.49M3.05N/AN/A$5.95 per share1.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
-$344.51MN/AN/AN/AN/A-2,483.94%-68.25%-62.43%N/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.85M-$0.67N/AN/AN/A-8,527.43%-95.51%-71.47%8/4/2026 (Estimated)
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$39.78MN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)
Palatin Technologies stock logo
PTN
Palatin Technologies
-$17.31MN/AN/AN/AN/AN/A-141.40%-58.08%9/2/2026 (Estimated)

Latest PTN, IMMP, CRDF, and AIFC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.1196N/AN/AN/A$0.06 millionN/A
5/18/2026Q1 2026
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
N/A-$2.14N/A-$2.14N/A$4.71 million
5/14/2026Q1 2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.13-$0.18-$0.05-$0.18$0.09 million$0.04 million
5/13/2026Q3 2026
Palatin Technologies stock logo
PTN
Palatin Technologies
-$1.2433-$0.37+$0.8733-$0.37$1.28 million$3.92 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Palatin Technologies stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
0.03
0.82
0.82
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
3.27
3.27
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
2.97
N/A
Palatin Technologies stock logo
PTN
Palatin Technologies
N/A
5.04
5.04

Institutional Ownership

CompanyInstitutional Ownership
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
6.27%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Palatin Technologies stock logo
PTN
Palatin Technologies
11.50%

Insider Ownership

CompanyInsider Ownership
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
0.21%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
8.50%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Palatin Technologies stock logo
PTN
Palatin Technologies
7.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALT5 Sigma Corporation stock logo
AIFC
ALT5 Sigma
170139.84 million139.54 millionN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2068.50 million62.68 millionOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021147.37 million142.85 millionOptionable
Palatin Technologies stock logo
PTN
Palatin Technologies
301.78 million1.65 millionN/A

Recent News About These Companies

Palatin Technologies (NYSEAMERICAN:PTN) Trading 1.7% Higher - Here's Why
July 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30913687
Palatin to Begin Trading on Nasdaq Stock Exchange
May 18, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/palatin-to-begin-trading-on-nasdaq-stock-exchange-302774038.html
Palatin Is Betting on the Next Generation of Obesity Drugs (NYSE: PTN)
May 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RYTM-Q/pressreleases/1931399/palatin-is-betting-on-the-next-generation-of-obesity-drugs-nyse-ptn/
Palatin Technologies, Inc. (AMEX:PTN) Q3 2026 Earnings Call Transcript
May 14, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/palatin-technologies-inc-amexptn-q3-2026-earnings-call-transcript-1762055/
Palatin Technologies Earnings Call: Partnerships, Progress, Risks
May 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/palatin-technologies-earnings-call-partnerships-progress-risks?utm_source=marketbeat.com&utm_medium=referral
Palatin Technologies Inc (PTN) Q3 2026 Earnings Call Highlights: Strategic Advances Amidst ...
May 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/palatin-technologies-inc-ptn-q3-230342249.html
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
May 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4904082-palatin-technologies-inc-ptn-q3-2026-earnings-call-transcript
Palatin Technologies GAAP EPS of -$0.37, revenue of $3.9M
May 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4591952-palatin-technologies-gaap-eps-of--037-revenue-of-39m?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=news?source=MarketBeat
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
May 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/palatin-reports-fiscal-third-quarter-2026-financial-results-and-provides-business-update-302770261.html
Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN)
March 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RYTM/pressreleases/880214/palatins-case-strengthens-as-rhythms-fda-approval-validates-hypothalamic-obesity-market-ptn/
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript
February 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4870981-palatin-technologies-inc-ptn-q2-2026-earnings-call-transcript
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
February 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/palatin-reports-second-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update-302688156.html
Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?
December 11, 2025  |  benzinga.comhttps://www.benzinga.com/markets/equities/25/12/49325529/why-are-palatin-technologies-ptn-shares-spiking-after-hours

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT5 Sigma stock logo

ALT5 Sigma NASDAQ:AIFC

$0.41 +0.04 (+10.49%)
As of 07/31/2026 04:00 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$0.86 +0.00 (+0.52%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$0.86 +0.01 (+1.12%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$0.38 +0.00 (+0.58%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$0.38 0.00 (0.00%)
As of 07/31/2026 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Palatin Technologies stock logo

Palatin Technologies NYSEAMERICAN:PTN

$7.70 -0.11 (-1.41%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$7.75 +0.05 (+0.65%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas